Pilehvari Asal, You Wen, Kimmick Gretchen, Bonilla Gloribel, Anderson Roger
Department of Public Health Sciences, University of Virginia, 560 Ray C Hunt Dr., Room 2107, Charlottesville, VA, USA.
University of Virginia Comprehensive Cancer Center, Charlottesville, VA, USA.
Breast Cancer Res Treat. 2025 Apr;210(3):575-582. doi: 10.1007/s10549-024-07593-3. Epub 2025 Jan 7.
While previous research has highlighted treatment delay inequities in early-stage breast cancer and identified potential contributing factors, there is limited research on disparities in treatment delays for metastatic breast cancer (MBC). This study investigates these disparities in MBC treatment initiation, aiming to identify key factors crucial for improving timely access to care.
Nationwide Flatiron Health electronic health records-derived deidentified database, including females aged 18+ diagnosed with either De novo or relapsed MBC in the U.S. between 2011 and 2022. Treatment delay, defined as > 60 days between diagnosis and first-line treatment, was assessed as a binary variable. T-tests and chi-squared tests analyzed patient characteristics (age, race, insurance, diagnosis stage, metastasis site, phenotypes, etc.) among delayed and non-delayed groups. Logistic regression evaluated the association between clinical and non-clinical factors and treatment delays.
Among 20,617 patients with MBC, nearly 27% experienced treatment delays. These patients were generally younger, uninsured, historically marginalized, and newly diagnosed. Risk ratio analysis showed patients with only Medicare without secondary coverage (RR: 2.34, 95% CI [1.06, 5.16]) and uninsured (RR: 2.18, 95% CI [1.01, 4.76]) had higher risk of delays compared to those with commercial insurance. Historically marginalized patients had higher delay risk, ranging from 6% for Black patients to 12% for patients with not documented race/ethnicity background (p = 0.03) compared to White patients."
Our study highlights significant disparities in MBC treatment delays. Patients from historically marginalized groups and those without health insurance coverage or with only Medicare coverage are highly likely to experience delays. Addressing these disparities is essential for equitable healthcare and improved outcomes.
虽然先前的研究强调了早期乳腺癌治疗延迟的不平等现象,并确定了潜在的影响因素,但关于转移性乳腺癌(MBC)治疗延迟差异的研究有限。本研究调查了MBC治疗开始方面的这些差异,旨在确定对于改善及时获得治疗至关重要的关键因素。
使用来自Flatiron Health的全国电子健康记录的去识别数据库,其中包括2011年至2022年期间在美国被诊断为新发或复发MBC的18岁及以上女性。治疗延迟定义为诊断与一线治疗之间间隔超过60天,作为二元变量进行评估。采用t检验和卡方检验分析延迟组和非延迟组患者的特征(年龄、种族、保险、诊断阶段、转移部位、表型等)。逻辑回归评估临床和非临床因素与治疗延迟之间的关联。
在20,617例MBC患者中,近27%经历了治疗延迟。这些患者通常较年轻、未参保、历史上处于边缘化地位且为新诊断患者。风险比分析显示,仅拥有医疗保险而无二次保险覆盖的患者(RR:2.34,95%CI[1.06,5.16])和未参保患者(RR:2.18,95%CI[1.01,4.76])与拥有商业保险的患者相比,延迟风险更高。历史上处于边缘化地位的患者延迟风险更高,与白人患者相比,黑人患者的延迟风险为6%,种族/族裔背景未记录的患者为12%(p = 0.03)。
我们的研究突出了MBC治疗延迟方面的显著差异。历史上处于边缘化群体的患者以及没有医疗保险覆盖或仅拥有医疗保险覆盖的患者极有可能经历延迟。解决这些差异对于实现公平医疗和改善治疗结果至关重要。